22UA:FRA
BioNTech
€78.10
arrow_downward
-1.88%(-1.50) 1D
Okt 16, 10:00:00 PM GMT+2 · EUR
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa 22UA...
Buksan
€80.15
Mataas
€81.25
Mababa
€78.10
Mkt. cap
22.03B
Avg. na dami
1.43K
Dami
602.00
Mataas nang 52-wk
€105.50
Mababa nang 52-wk
€68.00
Bilang ng mga empleyado
8K
Buksan
€80.15
Mataas
€81.25
Mababa
€78.10
Mkt. cap
22.03B
Avg. na dami
1.43K
Dami
602.00
Mataas nang 52-wk
€105.50
Mababa nang 52-wk
€68.00
Bilang ng mga empleyado
8K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
ad-hoc-news.de
·
1 oras ang nakalipas
BioNTech's BNT113 Readout Now Hinges on Overall Survival as Shares Test 52-Week Floor
24/7 Wall St.
·
20 oras ang nakalipas
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Pluang
·
2 araw ang nakalipas
BioNTech shares drop 7.13% after trial failure raises concerns over oncology program claims
Simply Wall Street
·
3 araw ang nakalipas
BioNTech Stock Faces Questions After Cancer Trial Missed Progression Free Survival Goal
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Tungkol sa BioNTech